Cargando…

Higher longitudinal brain white matter atrophy rate in aquaporin-4 IgG-positive NMOSD compared with healthy controls

We aimed to compare longitudinal brain atrophy in patients with neuromyelitis optica spectrum disorder (NMOSD) with healthy controls (HCs). The atrophy rate in patients with anti-aquaporin-4 antibody-positive NMOSD (AQP4 + NMOSD) was compared with age-sex-matched HCs recruited from the Japanese Alzh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Masuda, Hiroki, Mori, Masahiro, Hirano, Shigeki, Uzawa, Akiyuki, Uchida, Tomohiko, Muto, Mayumi, Ohtani, Ryohei, Aoki, Reiji, Hirano, Yoshiyuki, Kuwabara, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400628/ https://www.ncbi.nlm.nih.gov/pubmed/37537208 http://dx.doi.org/10.1038/s41598-023-38893-1

Ejemplares similares

Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Masuda, Hiroki, et al.
Publicado: (2022)

Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD
por: Masuda, Hiroki, et al.
Publicado: (2023)

Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder
por: Masuda, Hiroki, et al.
Publicado: (2017)

Difference in fatigue and pain between neuromyelitis optica spectrum disorder and multiple sclerosis
por: Masuda, Hiroki, et al.
Publicado: (2020)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 IgG‐Positive NMOSD
por: Wingerchuk, Dean M., et al.
Publicado: (2021)

The aquaporin4-IgG status and how it affects the clinical features and treatment response in NMOSD patients in Egypt
por: Kishk, Nirmeen A., et al.
Publicado: (2021)

AQP4-IgG autoimmunity in Japan and Germany: Differences in clinical profiles and prognosis in seropositive neuromyelitis optica spectrum disorders
por: Asseyer, Susanna, et al.
Publicado: (2021)

NMOSD IgG Impact Retinal Cells in Murine Retinal Explants
por: Wolf, Hannah Nora, et al.
Publicado: (2023)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
por: Fragoso, Diego Cardoso, et al.
Publicado: (2023)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

AQP4‐IgG positive paraneoplastic NMOSD: A case report and review
por: Ding, Manqiu, et al.
Publicado: (2021)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
por: Shosha, Eslam, et al.
Publicado: (2018)

Temporal Changes in Brain Perfusion in a Patient with Myoclonus and Ataxia Syndrome Associated with COVID-19
por: Osawa, Kenta, et al.
Publicado: (2022)

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
por: Jitprapaikulsan, Jiraporn, et al.
Publicado: (2020)

A Comparison of IgG Index and Oligoclonal Band in the Cerebrospinal Fluid for Differentiating between RRMS and NMOSD
por: Chen, Bo, et al.
Publicado: (2021)

A case report on recurrent area postrema syndrome in AQP4-IgG-positive NMOSD
por: Shrestha, Ramesh, et al.
Publicado: (2022)

Different clinical phenotypes of AQP4-IgG positive NMOSD in two first degree relatives
por: Ssemmanda, Salvatore, et al.
Publicado: (2023)

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
por: Kaneko, Kimihiko, et al.
Publicado: (2018)

Loss of Taste as an Initial Symptom of a “Facial Diplegia and Paresthesia” Variant of Guillain-Barré Syndrome
por: Hiraga, Akiyuki, et al.
Publicado: (2022)

An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD
por: Carnero Contentti, Edgar, et al.
Publicado: (2021)

Delayed Appearance of Brain Magnetic Resonance Imaging Abnormalities in a Patient with Glial Fibrillary Acidic Protein Astrocytopathy
por: Izumi, Michiko, et al.
Publicado: (2022)

Association between Cognitive Impairment and Hippocampal Subfield Volumes in Multiple System Atrophy
por: Sugiyama, Atsuhiko, et al.
Publicado: (2023)

Treatment and outcome of aquaporin-4 antibody–positive NMOSD: A multinational pediatric study
por: Paolilo, Renata Barbosa, et al.
Publicado: (2020)

Radiologically isolated syndrome and the possibility of preclinical disease activity in aquaporin-4 antibody NMOSD
por: Rotstein, Dalia L
Publicado: (2022)

Relapse of Neuromyelitis Optica Spectrum Disorder Associated with Intravenous Lidocaine
por: Uzawa, Akiyuki, et al.
Publicado: (2011)

Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment
por: Uzawa, Akiyuki, et al.
Publicado: (2022)

IgG4-related Disease Manifesting as Gastroduodenal Ulcer Diagnosed by an Endoscopic Biopsy
por: Muto, Osamu, et al.
Publicado: (2020)

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
por: Dinoto, Alessandro, et al.
Publicado: (2022)

Identification of geraldol as an inhibitor of aquaporin-4 binding by NMO-IgG
por: Wang, Jie, et al.
Publicado: (2020)

Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD
por: Akaishi, Tetsuya, et al.
Publicado: (2020)

Evaluation of brain lesion distribution criteria at disease onset in differentiating MS from NMOSD and MOG-IgG-associated encephalomyelitis
por: Hyun, Jae-Won, et al.
Publicado: (2018)

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
por: Schroeder-Castagno, Maria, et al.
Publicado: (2022)

Pareidolia in Parkinson's Disease and Multiple System Atrophy
por: Kurumada, Kentaro, et al.
Publicado: (2021)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Aquaporin-4 IgG autoimmune syndrome and immunoreactivity associated with thyroid cancer
por: Soelberg, Kerstin, et al.
Publicado: (2016)

Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica
por: Uzawa, Akiyuki, et al.
Publicado: (2010)

Correction: CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
Publicado: (2019)

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
por: Fadda, Giulia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qrhms8fkd9f9sdki92fu24glo6